TY - JOUR
T1 - Pneumococcal carriage and changes in serotype distribution post- PCV13 introduction in children in Matiari, Pakistan
AU - Iqbal, Izn
AU - Shahid, Shahira
AU - Kanwar, Samiah
AU - Kabir, Furqan
AU - Umrani, Fayaz
AU - Ahmed, Sheraz
AU - Khan, Waqasuddin
AU - Qazi, Muhammad Farrukh
AU - Aziz, Fatima
AU - Muneer, Sahrish
AU - Kalam, Adil
AU - Hotwani, Aneeta
AU - Mehmood, Junaid
AU - Qureshi, Abdul Khalique
AU - Hasan, Zahra
AU - Shakoor, Sadia
AU - Mirza, Shaper
AU - McGee, Lesley
AU - Lo, Stephanie W.
AU - Kumar, Narender
AU - Azam, Iqbal
AU - Bentley, Stephen D.
AU - Jehan, Fyezah
AU - Nisar, Muhammad Imran
N1 - Publisher Copyright:
© 2024
PY - 2024/10/3
Y1 - 2024/10/3
N2 - Background: In early 2021, the 10-valent Pneumococcal conjugate vaccine (PCV10) was replaced with 13-valent (PCV13) by the federal directorate of immunization (FDI), Pakistan. We assessed the impact of a higher valent vaccine, PCV13, on the serotype distribution of nasopharyngeal carriage in rural Pakistan. Methods: Children <2 years were randomly selected from two rural union councils of Matiari, Sindh in Pakistan between September–October,2022. Clinical, sociodemographic and vaccination histories were recorded. Nasopharyngeal swabs were collected and processed at Infectious Disease Research Laboratory, Aga Khan University, Karachi. Whole genome sequencing was performed on the culture positive isolates. Results: Of the 200 children enrolled, pneumococcus was detected in 140(70 %) isolates. Majority of age-eligible children (60.1 %,110/183) received 3 PCV13 doses. PCV10 carriage declined from 13.2 %(78/590) in 2017/18 to 7.2 % (10/140) in 2022, additional PCV13 serotypes (3, 6A/6C and 19A) decreased from 18.5 %(109/590) to 11.4 %(16/140) while non-PCV13 serotypes increased from 68.3 %(403/590) to 81.4 %(114/140). There were 88.5 %(n = 124), 80.7 %(n = 113), 55.0 %(n = 77), and 46.0 %(n = 65) isolates predicted to be resistant to cotrimoxazole, penicillin(meningitis cut-off), tetracycline, and erythromycin respectively. Conclusion: Replacing PCV10 with PCV13 rapidly decreased prevalence of PCV13 carriage among vaccinated children in Matiari, Pakistan. Vaccine-driven selection pressure may have been responsible for the increase of non-PCV13 serotypes.
AB - Background: In early 2021, the 10-valent Pneumococcal conjugate vaccine (PCV10) was replaced with 13-valent (PCV13) by the federal directorate of immunization (FDI), Pakistan. We assessed the impact of a higher valent vaccine, PCV13, on the serotype distribution of nasopharyngeal carriage in rural Pakistan. Methods: Children <2 years were randomly selected from two rural union councils of Matiari, Sindh in Pakistan between September–October,2022. Clinical, sociodemographic and vaccination histories were recorded. Nasopharyngeal swabs were collected and processed at Infectious Disease Research Laboratory, Aga Khan University, Karachi. Whole genome sequencing was performed on the culture positive isolates. Results: Of the 200 children enrolled, pneumococcus was detected in 140(70 %) isolates. Majority of age-eligible children (60.1 %,110/183) received 3 PCV13 doses. PCV10 carriage declined from 13.2 %(78/590) in 2017/18 to 7.2 % (10/140) in 2022, additional PCV13 serotypes (3, 6A/6C and 19A) decreased from 18.5 %(109/590) to 11.4 %(16/140) while non-PCV13 serotypes increased from 68.3 %(403/590) to 81.4 %(114/140). There were 88.5 %(n = 124), 80.7 %(n = 113), 55.0 %(n = 77), and 46.0 %(n = 65) isolates predicted to be resistant to cotrimoxazole, penicillin(meningitis cut-off), tetracycline, and erythromycin respectively. Conclusion: Replacing PCV10 with PCV13 rapidly decreased prevalence of PCV13 carriage among vaccinated children in Matiari, Pakistan. Vaccine-driven selection pressure may have been responsible for the increase of non-PCV13 serotypes.
KW - Bacterial genomics
KW - Genomic epidemiology
KW - Pneumococcal carriage
KW - Pneumococcal conjugate vaccine
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=85201487324&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2024.126238
DO - 10.1016/j.vaccine.2024.126238
M3 - Article
AN - SCOPUS:85201487324
SN - 0264-410X
VL - 42
JO - Vaccine
JF - Vaccine
IS - 23
M1 - 126238
ER -